These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 11126200)

  • 1. Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment.
    Huang L; Pardee AB
    Mol Med; 2000 Oct; 6(10):849-66. PubMed ID: 11126200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suberoylanilide hydroxamic acid-induced specific epigenetic regulation controls Leptin-induced proliferation of breast cancer cell lines.
    Feng X; Han H; Zou D; Zhou J; Zhou W
    Oncotarget; 2017 Jan; 8(2):3364-3379. PubMed ID: 27926517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells.
    Munster PN; Troso-Sandoval T; Rosen N; Rifkind R; Marks PA; Richon VM
    Cancer Res; 2001 Dec; 61(23):8492-7. PubMed ID: 11731433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells.
    Kumagai T; Wakimoto N; Yin D; Gery S; Kawamata N; Takai N; Komatsu N; Chumakov A; Imai Y; Koeffler HP
    Int J Cancer; 2007 Aug; 121(3):656-65. PubMed ID: 17417771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
    Shi YK; Li ZH; Han XQ; Yi JH; Wang ZH; Hou JL; Feng CR; Fang QH; Wang HH; Zhang PF; Wang FS; Shen J; Wang P
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2.
    Bali P; Pranpat M; Swaby R; Fiskus W; Yamaguchi H; Balasis M; Rocha K; Wang HG; Richon V; Bhalla K
    Clin Cancer Res; 2005 Sep; 11(17):6382-9. PubMed ID: 16144943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites.
    Huang L; Sowa Y; Sakai T; Pardee AB
    Oncogene; 2000 Nov; 19(50):5712-9. PubMed ID: 11126357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL.
    Butler LM; Liapis V; Bouralexis S; Welldon K; Hay S; Thai le M; Labrinidis A; Tilley WD; Findlay DM; Evdokiou A
    Int J Cancer; 2006 Aug; 119(4):944-54. PubMed ID: 16550602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA).
    Almenara J; Rosato R; Grant S
    Leukemia; 2002 Jul; 16(7):1331-43. PubMed ID: 12094258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticancer effects of the MHY218 novel hydroxamic acid-derived histone deacetylase inhibitor in human ovarian cancer cells.
    Jeon HS; Ahn MY; Park JH; Kim TH; Chun P; Kim WH; Kim J; Moon HR; Jung JH; Kim HS
    Int J Oncol; 2010 Aug; 37(2):419-28. PubMed ID: 20596669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice.
    Shankar S; Davis R; Singh KP; Kurzrock R; Ross DD; Srivastava RK
    Mol Cancer Ther; 2009 Jun; 8(6):1596-605. PubMed ID: 19509267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of radiation response by histone deacetylase inhibition.
    Chinnaiyan P; Vallabhaneni G; Armstrong E; Huang SM; Harari PM
    Int J Radiat Oncol Biol Phys; 2005 May; 62(1):223-9. PubMed ID: 15850925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell Cycle Arrest and Cytotoxic Effects of SAHA and RG7388 Mediated through p21
    Natarajan U; Venkatesan T; Radhakrishnan V; Samuel S; Rasappan P; Rathinavelu A
    Medicina (Kaunas); 2019 Jan; 55(2):. PubMed ID: 30700046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo.
    Luong QT; O'Kelly J; Braunstein GD; Hershman JM; Koeffler HP
    Clin Cancer Res; 2006 Sep; 12(18):5570-7. PubMed ID: 17000694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells.
    Li JP; Yang YX; Liu QL; Pan ST; He ZX; Zhang X; Yang T; Chen XW; Wang D; Qiu JX; Zhou SF
    Drug Des Devel Ther; 2015; 9():1627-52. PubMed ID: 25834401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effects of histone deacetylase inhibitors on p53 target gene expression, cell cycle and apoptosis in MCF-7 breast cancer cells.
    Knutson AK; Welsh J; Taylor T; Roy S; Wang WL; Tenniswood M
    Oncol Rep; 2012 Mar; 27(3):849-53. PubMed ID: 22159450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticancer effects of suberoylanilide hydroxamic acid in esophageal squamous cancer cells in vitro and in vivo.
    Tzao C; Jin JS; Chen BH; Chung HY; Chang CC; Hsu TY; Sun GH
    Dis Esophagus; 2014; 27(7):693-702. PubMed ID: 24033428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suberoylanilide hydroxamic acid increases anti-cancer effect of tumor necrosis factor-α through up-regulation of TNF receptor 1 in lung cancer cells.
    You BR; Han BR; Park WH
    Oncotarget; 2017 Mar; 8(11):17726-17737. PubMed ID: 28099148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel gamma-lactam-based histone deacetylase inhibitor potently inhibits the growth of human breast and renal cancer cells.
    Kwon HK; Ahn SH; Park SH; Park JH; Park JW; Kim HM; Park SK; Lee K; Lee CW; Choi E; Han G; Han JW
    Biol Pharm Bull; 2009 Oct; 32(10):1723-7. PubMed ID: 19801834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.